SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Relmada Therapeutics (RLMD) Reports 18-Month NDV-01 Results, Targets Year-End INDs

Relmada reported initial 18-month results from its ongoing Phase 2 NDV-01 study, citing extended durability of complete response and favorable tolerability. It remains on track to submit INDs for NDV-01 and sepranolone by year-end 2026.Material DetailsContext by AI AnalystThis is an early-stage cli…

RLMD

Related stories